South Carolina Attorney General Alan Wilson led a 37-state coalition that wants the FDA to take action against manufacturers ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Wegovy and Ozempic have the same active ingredient, semaglutide. “Technically, they are exactly the same,” Dr. Maria Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic’s ...

A sudden drop in blood pressure of just 20 mmHg, such as a change in systolic pressure from 100 mmHg to 80 mmHg could cause symptoms, and bigger drops could be related to a medical emergency.

aCardiovascular R&D Centre – UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.